

Professional Information

SCHEDULING STATUS

S3

1. NAME OF THE MEDICINE

ALAPREN 5 TABLETS

ALAPREN 10 TABLETS

ALAPREN 20 TABLETS

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

ALAPREN 5 TABLETS

Each tablet contains

Enalapril maleate 5 mg

Contains sugar: Lactose 40 mg per tablet

Contains sodium: 0,131 mg per tablet

ALAPREN 10 TABLETS

Each tablet contains

Enalapril maleate 10 mg

Contains sugar: Lactose 80 mg per tablet

Contains sodium: 0,262 mg per tablet

ALAPREN 20 TABLETS

Each tablet contains

Enalapril maleate 20 mg

Contains sugar: Lactose 80 mg per tablet

Contains sodium: 0,262 mg per tablet

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Tablet

ALAPREN 5 TABLETS

White to off-white round, biconvex uncoated tablets debossed with '5' on one side and plain on other side.

ALAPREN 10 TABLETS

Pink, round biconvex uncoated tablets debossed with '10' on one side and plain on other side.

ALAPREN 20 TABLETS

Peach coloured round, biconvex, uncoated tablets debossed with '20' on one side and plain on other side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Treatment of hypertension.

Treatment of heart failure: **ALAPREN TABLETS** is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients **ALAPREN TABLETS** improves symptoms, increases survival, and decreases the frequency of hospitalization.

Asymptomatic left ventricular dysfunction: In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction < 35 %), enalapril decreases the rate of development of overt heart failure and decreases the incidence of hospitalisation for heart failure.

4.2 Posology and method of administration

Posology

***ALAPREN TABLETS** is not available in a 2,5 mg strength. Please use an alternative enalapril 2,5 mg product available on the market,

Since food does not interfere with the absorption of **ALAPREN TABLETS**, the dose may be administered before, during or after meals.

Essential hypertension: The initial dose is 10 to 20 mg depending on the degree of hypertension and is given once daily. In mild hypertension the recommended initial dose is 10 mg daily. For other degrees of hypertension the initial dose is 20 mg daily. The usual maintenance dose is one 20 mg tablet taken once daily. The dosage should be adjusted according to the needs of the patient.

Concomitant diuretic therapy in hypertension: Symptomatic hypotension may occur following the initial dose of **ALAPREN TABLETS**; this is more likely in patients who are being treated currently with diuretics. Caution is recommended, therefore, since these patients may be volume or salt depleted. The diuretic therapy should be discontinued for 2-3 days prior to initiation of therapy with **ALAPREN TABLETS**. If this is not possible, the initial dose of enalapril should be low (5 mg or less) to determine the initial effect on the blood pressure. Dosage should then be adjusted according to the needs of the patient.

Use in the elderly (over 65 years): Therapy should be initiated with **ALAPREN TABLETS** in a dose of 2,5 mg. The hypotensive response to **ALAPREN TABLETS** may be greater in elderly patients.

Heart failure/ asymptomatic left ventricular dysfunction: In such patients the recommended starting dose of **ALAPREN TABLETS** is 2,5 mg once daily initiated under medical supervision to determine the initial effect on the blood pressure. It is important that therapy is initiated in hospital for patients with severe heart failure. The dose of **ALAPREN TABLETS** should be titrated gradually to a maintenance dose of 20 mg daily given as a single dose or two divided doses, according to the tolerability of the patient.

The dose titration of **ALAPREN TABLETS** should be performed over two to four weeks or more rapidly in the presence of residual signs and symptoms of heart failure. The patient's blood pressure, renal function and serum potassium must be monitored closely both before and during treatment with **ALAPREN TABLETS** because hypotension and consequent renal failure have been reported. Patients who are treated with diuretics should have the diuretic dose reduced, if possible, before starting treatment with **ALAPREN TABLETS**. In case hypotension develops following the initial dose of **ALAPREN TABLETS**, this does not imply that hypotension will recur during chronic therapy with **ALAPREN TABLETS** and does not preclude continued use of **ALAPREN TABLETS**.

Dosage in renal Insufficiency:

(See Section 4.4., *Impaired Renal Function*).

Generally the intervals between the administration of enalapril should be prolonged and/or the dosage reduced.

Renal status	Creatinine Clearance (ml/min)	Initial Dose (mg/day)
Mild impairment	< 80 > 50	5
Moderate impairment	< 50 > 30	2,5

Serum potassium also should be regularly monitored (see Section 4.4 and 4.5).

Method of administration

Oral use.

4.3 Contraindications

- **ALAPREN TABLETS** should not be used in patients with known hypersensitivity to enalapril or any of the excipients of **ALAPREN TABLETS** (listed in section 6.1).

- A history of angioedema relating to previous ACE inhibitor or angiotensin receptor blockers (ARBs) treatment: Such patients must never again be given these medicines.
- Hereditary or idiopathic angioedema.
- Hypertrophic obstructive cardiomyopathy (HOCM).
- Severe renal function impairment (creatinine clearance less than 30 ml/min).
- Bilateral renal artery stenosis.
- Renal artery stenosis in patients with a single kidney.
- Aortic stenosis.
- Concomitant therapy with potassium sparing diuretics such as spironolactone, triamterene, amiloride.
- Porphyria.
- Lithium therapy: Concomitant administration with **ALAPREN TABLETS** may lead to toxic blood concentrations of lithium.
- Pregnancy and lactation (see Section 4.4 and 4.6)
- The concomitant use of **ALAPREN TABLETS** with aliskiren-containing products is contraindicated. (see Section 4.4 and 4.5)
- Concomitant use of fluoroquinolones with ACE inhibitors/renin-angiotensin blockers is contraindicated in patients with moderate to severe renal impairment.

4.4 Special warnings and precautions for use

Should a woman become pregnant while receiving **ALAPREN TABLETS**, the treatment must be stopped promptly and switched to a different class of medicine. Should a woman contemplate pregnancy, the doctor should institute alternative medication. (See Section 4.3 and 4.6)

Dual blockade of the renin-angiotensin-aldosterone system (RAAS) There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers (ARBs) or aliskiren may increase the risk of hypotension, hyperkalaemia and decreases renal function (including acute renal failure). Dual blockade of RAAS through the combined use of **ALAPREN TABLETS** and aliskiren is therefore contraindicated (see Section 4.3). **ALAPREN TABLETS** should not be used concomitantly with aliskiren. (see Section 4.3).

ALAPREN TABLETS can cause foetal and neonatal morbidity and mortality when administered to pregnant women during the 2nd and 3rd trimesters (see Section 4.3 and 4.4).

Assessment of renal function prior to initiation of **ALAPREN TABLETS** and during treatment with **ALAPREN TABLETS** should be included in the evaluation of patient, where appropriate.

Symptomatic hypotension: Symptomatic hypotension can occur especially in patients who are volume-depleted e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea or vomiting (see Section 4.5 and 4.8). In patients with heart failure, with or without associated renal insufficiency, symptomatic hypotension is most likely to occur in those with more severe degrees of heart failure, as reflected by the use of high doses of loop diuretics, hyponatraemia or functional renal impairment (see Section 4.2) for management of these patients). In these patients, therapy should be started under medical supervision and the patient should be monitored closely whenever the dose of **ALAPREN TABLETS** and/or diuretic is adjusted. Similarly, patients with ischaemic heart or cerebrovascular disease may develop an excessive fall in blood pressure which could result in a myocardial infarction or cerebrovascular accident.

If hypotension develops, suitable management including placing the patient in a supine position and, if necessary, an intravenous infusion of normal saline may be required. A transient hypotensive response is not a contraindication to further doses, which can be given with monitoring once the blood pressure is increased after volume expansion.

Some patients with heart failure who have normal or low blood pressure could develop additional lowering of systemic blood pressure following **ALAPREN TABLETS** administration. If symptomatic hypotension occurs, a reduction of dose of **ALAPREN TABLETS** and/or discontinuation of the diuretic may be necessary (see Section 4.2).

Impaired Renal Function: Caution should be exercised when using **ALAPREN TABLETS** in patients with renal insufficiency. Such patients may require reduced or less frequent doses (see Section 4.2). The renal function should be monitored before and during therapy in those with renal insufficiency.

Renovascular hypertension: **ALAPREN TABLETS** is contraindicated in renovascular hypertension (see Section 4.3).

Kidney Transplantation: There is no experience regarding the administration of **ALAPREN TABLETS** in patients with recent kidney transplantation. Treatment with **ALAPREN TABLETS** is therefore not recommended.

Concomitant use of fluoroquinolones and ACE inhibitors/renin-angiotensin receptor blockers may precipitate acute kidney injury in patients, especially those with moderate to severe renal impairment and elderly patients (see Section 4.3). Renal function should be assessed before initiating treatment, and monitored during treatment, with fluoroquinolones or ACE inhibitors/renin-angiotensin receptor blockers.

Hepatic failure: Patients receiving **ALAPREN TABLETS** who develop jaundice or marked elevations of hepatic enzymes should discontinue **ALAPREN TABLETS** and receive appropriate medical follow-up.

Neutropenia/Agranulocytosis:

Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors including **ALAPREN TABLETS**. **ALAPREN TABLETS** should be used

with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing impaired renal function. Some of these patients developed serious infections which in a few instances did not respond to intensive antibiotic therapy.

Hypersensitivity/Angioneurotic oedema: Angioneurotic oedema of the face, extremities, lips, tongue, glottis and/or larynx has been seen to occur following treatment with **ALAPREN TABLETS**. This may occur at any time during treatment. In such cases, **ALAPREN TABLETS** should be discontinued immediately and appropriate monitoring should be taken to ensure complete resolution of symptoms prior to discharging the patient. Angioneurotic oedema associated with laryngeal oedema may be fatal. Involvement of the tongue, glottis or larynx, likely to cause airways obstruction, necessitates emergency measures such as prompt administration of subcutaneous adrenaline (0,3-0,5 ml, 1: 1000).

Black patients receiving **ALAPREN TABLETS** have been reported to have a higher incidence of angioedema compared with non-black patients.

Patients with a history of angioedema unrelated to **ALAPREN TABLETS** should be considered to be at increased risk of angioedema while receiving **ALAPREN TABLETS** (see also Section 4.3

Anaphylactic reactions during hymenoptera desensitisation: Patients receiving **ALAPREN TABLETS** during desensitisation with hymenoptera venom (e.g. bee or wasp venom) have been found to experience life threatening hypersensitivity reactions. Temporarily withholding **ALAPREN TABLETS** therapy prior to each desensitisation can help avert such reactions.

Hypersensitivity reactions during LDL apheresis: Less frequently, patients receiving ACE inhibitors during low density lipoprotein (LDL)-apheresis with dextran sulphate have experienced life-

threatening hypersensitivity reactions. These reactions may be avoided by withholding **ALAPREN TABLETS** therapy prior to each apheresis.

Haemodialysis patients: In patients dialysed with high-flux membranes and treated concomitantly with **ALAPREN TABLETS** a high incidence of anaphylactoid reactions have been reported. It is recommended that in such patients a different type of dialysis membrane or a different class of antihypertensive agent should be used.

Hypoglycaemia: Diabetic patients treated with oral antidiabetic agents or insulin starting **ALAPREN TABLETS**, should be told to closely monitor for hypoglycaemia, especially during the first month of combined use.

Surgery/Anaesthesia: **ALAPREN TABLETS** blocks the formation of angiotensin-II secondary to compensatory renin release in patients undergoing major surgery or during anaesthesia with agents that cause hypotension. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.

Serum potassium: See Section 4.5.

Excipients

ALAPREN TABLETS contain lactose monohydrate.

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

ALAPREN TABLETS contain sodium

This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'

4.5 Interaction with other medicines and other forms of interaction

Dual blockade of the RAAS with ARBs, ACE inhibitors, or aliskiren

Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (see Section 4.3 and 4.4).

Antihypertensive Therapy

The combination of **ALAPREN TABLETS** with other antihypertensive medicines may increase the antihypertensive effect, especially in combination with diuretics.

The combination of **ALAPREN TABLETS** with β -adrenergic blocking agents and methyldopa or calcium entry blockers potentiates the hypotensive effects of **ALAPREN TABLETS**.

Ganglionic blocking agents or adrenergic blocking agents, combined with **ALAPREN TABLETS**, should only be administered with careful observation of the patient.

Because of lack of experience, concomitant treatment of **ALAPREN TABLETS** with calcium antagonists is not recommended.

Concomitant use with nitroglycerine and other nitrates, or other vasodilators, may increase the risk of hypotension.

Serum Lithium

Lithium elimination may be reduced. See Section 4.3.

Serum Potassium

Risk factors for the development of hyperkalaemia include renal insufficiency, diabetes mellitus and concomitant use of potassium-sparing diuretics (e.g. spironolactone, triamterene, or amiloride), potassium supplements, or potassium containing salt substitutes. **ALAPREN TABLETS** may elevate serum potassium levels in patients with renal impairment. The use of potassium

supplements, potassium sparing diuretics or potassium containing salt substitutes particularly in patients with impaired renal function may lead to a significant increase in serum potassium. See Section 4.3.

Non-steroidal anti-inflammatory medicines including selective cyclooxygenase-2 inhibitors

Non-steroidal anti-inflammatory medicines (NSAIDs) including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors) may reduce the antihypertensive effect of **ALAPREN TABLETS**. The co-administration of NSAIDs (including COX-2 inhibitors) with **ALAPREN TABLETS** exert an additive effect on the increase in serum potassium, and may result in a deterioration of renal function, including acute renal failure, especially in patients with compromised renal function (such as the elderly or patients who are volume-depleted, including those on diuretic therapy).

Gold

Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant **ALAPREN TABLETS** therapy.

Antidiabetics

Concomitant administration of **ALAPREN TABLETS** and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycaemia. This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment.

Others

Concomitant use of general anaesthetic medicinal products, tricyclic antidepressants and antipsychotics with **ALAPREN TABLETS** may result in further reduction of blood pressure.

Concomitant administration of allopurinol, cytostatic or immuno-suppressive agents, systemic corticosteroids or procainamide with **ALAPREN TABLETS** may increase the risk for leucopenia (see Section 4.4.

Neutropenia/Agranulocytosis).

Concomitantly administered cyclosporin increases the risk of hyperkalaemia with **ALAPREN TABLETS**.

Since sympathomimetics may reduce the antihypertensive effects of **ALAPREN TABLETS**, careful monitoring of blood pressure should occur when these medicines are used concomitantly with **ALAPREN TABLETS**.

Alcohol enhances the hypotensive effect of concomitantly administered **ALAPREN TABLETS**.

Concomitant use of fluoroquinolones and ACE inhibitors/renin-angiotensin receptor blockers may precipitate acute kidney injury. See Section 4.3

A case series of 16 reports of acute kidney injury (AKI) associated with enalapril and ciprofloxacin as co-suspect or interacting medicines was identified in Vigibase, the WHO global database of individual case safety reports. Analysis of 11 cases indicated that in most patients although clinical conditions and a number of medicines were likely to have increased their risk of AKI, including ACE inhibitor-related AKI, the event did not occur until after a ciprofloxacin prescription, lending weight to ciprofloxacin being the cause or a combined action of ciprofloxacin and enalapril. Furthermore, the interaction between ACE inhibitors and fluoroquinolones to precipitate acute kidney injury is a class effect for all ACE inhibitors and not just enalapril, and also a class effect of all the fluoroquinolones not just with ciprofloxacin. Thus, concomitant use of fluoroquinolones and ACE inhibitors/renin-angiotensin receptor blockers may precipitate acute kidney injury. See Section 4.3

4.6 Fertility, pregnancy and lactation

The use of **ALAPREN TABLETS** is contraindicated during pregnancy. Pregnant women should be informed of the potential hazards to the foetus and must not take **ALAPREN TABLETS** during

pregnancy (see Section 4.3). Patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with **ALAPREN TABLETS** should be stopped immediately and if appropriate, alternative therapy should be started. Foetal exposure to ACE inhibitors during the first trimester of pregnancy has been reported to be associated with an increased risk of malformations of the cardiovascular (atrial and/or ventricular septal defect, pulmonic stenosis, patent ductus arteriosus) and central nervous system (microcephaly spina bifida) and of kidney malformations. **ALAPREN TABLETS** passes through the placenta and can be presumed to cause disturbance in foetal blood pressure regulatory mechanisms. Oligohydramnios as well as hypotension, oliguria and anuria in new-borns, have been reported after administration of **ALAPREN TABLETS** during the second and third trimester. Cases of defective skull ossification have been observed. Prematurity and low birth mass can occur (see Section 4.3).

Lactation - Enalapril and enalaprilat are secreted into the breast milk.

ALAPREN TABLETS is contraindicated in women breastfeeding their babies.

4.7 Effects on ability to drive and use machines

ALAPREN TABLETS may cause dizziness or weariness. Patients should be warned not to drive or use machines, until their individual susceptibility to the effects of **ALAPREN TABLETS** is known.

4.8 Undesirable effects

System Organ Class	Frequent	Less frequent
Blood and the lymphatic system disorders		Anaemia (including aplastic and haemolytic), neutropenia, decreases in hemoglobin, decreases in hematocrit, thrombocytopenia, agranulocytosis, bone marrow depression, pancytopenia, lymphadenopathy, autoimmune diseases.
Immune system disorders		Anaphylactoid reactions, hypersensitivity/angioneurotic oedema: angioedema of the face, extremities, lips, tongue, glottis and/or larynx.

Endocrine disorders		Syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Metabolism and nutrition disorders		Hypoglycaemia (see Section 4.4
Nervous system disorders	Headache, depression.	Confusion, somnolence, insomnia, nervousness, paraesthesia, vertigo, dream abnormality, sleep disorders.
Eye disorders	Blurred vision.	
Ear and labyrinth disorders		Tinnitus.
Cardiac disorders	Dizziness, hypotension (including orthostatic hypotension), syncope, chest pain, rhythm disturbances, angina pectoris, tachycardia.	Raynaud's phenomenon, orthostatic hypotension, palpitations, flushing, myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients (see Section 4.4
Respiratory, thoracic and mediastinal disorders	Cough, dyspnoea.	Rhinorrhoea, sore throat and hoarseness, bronchospasm/asthma, pulmonary infiltrates, rhinitis, allergic alveolitis/eosinophilic pneumonia.
Gastrointestinal disorders	Nausea, diarrhoea, abdominal pain, taste alteration.	Ileus, pancreatitis, vomiting, dyspepsia, constipation, anorexia, gastric irritations, dry mouth, peptic ulcer, stomatitis/aphthous ulcerations, glossitis, intestinal angioedema.
Hepatobiliary disorders		Hepatic failure, hepatitis – either hepatocellular or cholestatic, hepatitis including necrosis, cholestasis (including jaundice).

Skin and subcutaneous tissue disorders	Rash.	Diaphoresis, pruritus, urticaria, alopecia, erythema multiforme, Stevens-Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, pemphigus, erythroderma. A symptom complex has been reported which may include some or all of the following: fever, serositis, vasculitis, myalgia/myositis, arthralgia/arthritis, a positive anti-nuclear antibody (ANA), elevated erythrocyte sedimentation rate (ESR), eosinophilia, and leukocytosis. Rash, photosensitivity or other dermatologic manifestations may occur.
Musculoskeletal and connective tissue disorders		Muscle cramps.
Renal and urinary disorders		Renal dysfunction, renal failure, proteinuria, oliguria.
Reproductive system and breast disorders		Impotence, gynaecomastia.
General disorders and administration site conditions	Asthenia, fatigue.	Flushing, malaise, fever.
Investigations	Hyperkalaemia, increases in serum creatinine.	Increases in blood urea, hyponatraemia, elevations of liver enzymes, elevations of serum bilirubin.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions to SAHPRA via the “6.04 Adverse Drug Reaction

Reporting Form”, found online under SAHPRA’s publications:

<https://www.sahpra.org.za/Publications/Index/>

4.9 Overdose

Limited data are available for overdosage in humans. The most prominent feature of overdosage is hypotension, six hours after ingestion of the tablets, as well as stupor.

Symptoms associated with overdosage of **ALAPREN TABLETS** may include circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety, and cough.

The recommended treatment of overdosage with **ALAPREN TABLETS** is symptomatic and supportive. An intravenous infusion of 0,9 % sodium chloride may be considered. If available, treatment with angiotensin II infusion and/or intravenous sympathomimetics may also be considered.

ALAPREN TABLETS may be removed from the general circulation by haemodialysis. Vital signs, serum electrolytes and creatinine concentrations should be monitored.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Category and class: A 7.1.3 Vascular medicines - Other hypotensives

Pharmacotherapeutic group: Angiotensin Converting Enzyme (ACE) inhibitor- ATC Code: C09AA02

Following oral administration and absorption, enalapril is hydrolysed to enalaprilat which is a non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor. Enalapril is a derivative of two amino acids; L-alanine and L-proline. ACE is a peptidyl dipeptidase which catalyses the conversion of angiotensin I to the pressor substance angiotensin II. This results in reduced plasma renin activity and decreased aldosterone secretion. The blood pressure lowering effect of enalapril is primarily through suppression of the renin- angiotensin- aldosterone system.

5.2 Pharmacokinetic properties

Absorption:

Oral enalapril is absorbed, with peak serum concentrations of enalapril occurring within one hour. Based on urinary recovery, the extent of absorption of enalapril from oral enalapril tablet is approximately 60 %. The absorption of oral enalapril is not influenced by the presence of food in the gastrointestinal tract.

Following absorption, oral enalapril is rapidly and extensively hydrolysed to enalaprilat, an angiotensin converting enzyme inhibitor. Peak serum concentrations of enalaprilat occur about 4 hours after an oral dose of enalapril tablet. The effective half-life of enalaprilat following multiple doses of oral enalapril is 11 hours. In subjects with normal renal function, steady-state serum concentrations of enalaprilat were reached after 4 days of treatment.

Distribution:

Over the range of concentrations which are therapeutically relevant, enalaprilat binding to human plasma proteins does not exceed 60 %.

Biotransformation:

Except for conversion to enalaprilat, there is no evidence for significant metabolism of enalapril.

Excretion:

Excretion of enalaprilat is primarily renal. The principal components in urine are enalaprilat, accounting for about 40 % of the dose, and intact enalapril (about 20 %).

Renal impairment:

The exposure of enalapril and enalaprilat is increased in patients with renal insufficiency. In patients with mild to moderate renal insufficiency (creatinine clearance 40-60 ml/min) steady state AUC was approximately two-fold higher than in patients with normal renal function after administration of 5 mg once daily. In severe renal impairment (creatinine clearance \leq 30 ml/min), AUC was increased approximately 8-fold. The effective half-life of enalaprilat following multiple doses of enalapril maleate is prolonged at this level of renal insufficiency and time to steady state is delayed (see Section 4.2, Dosage in Renal Insufficiency). Enalaprilat may be removed from the general circulation by haemodialysis.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

ALAPREN 5 TABLETS

- Colloidal anhydrous silica,
- Croscarmellose sodium,
- Lactose,
- Maleic acid,
- Microcrystalline cellulose,
- Zinc stearate.

ALAPREN 10 TABLETS

- Colloidal anhydrous silica,
- Croscarmellose sodium,

- Ferric oxide red (CI No. 77491),
- Lactose,
- Maleic acid,
- Microcrystalline cellulose,
- Zinc stearate.

ALAPREN 20 TABLETS

- Colloidal anhydrous silica,
- Croscarmellose sodium,
- Ferric oxide red (CI No. 77491),
- Ferric oxide yellow (CI No. 77492),
- Lactose,
- Maleic acid,
- Microcrystalline cellulose,
- Zinc stearate.

6.2 Incompatibilities

Not applicable

6.3 Shelf life

36 months

6.4 Special precautions for storage

Store at or below 25 °C, protected from moisture.

6.5 Nature and contents of container

ALAPREN 5 TABLETS: Carton containing 4 blister strips of 7 tablets in each blister.

ALAPREN 10 TABLETS: Carton containing 4 blister strips of 7 tablets in each blister.

ALAPREN 20 TABLETS: Carton containing 4 blister strips of 7 tablets in each blister.

6.6 Special precautions for disposal

No special requirements.

7. HOLDER OF CERTIFICATE OF REGISTRATION

Ranbaxy Pharmaceuticals (Pty) Ltd

14 Lautre Road

Stormill, Ext. 1

Roodepoort, 1724

South Africa

8. REGISTRATION NUMBER(S)

ALAPREN 5 TABLETS: 34/7.1.3/0014

ALAPREN 10 TABLETS: 34/7.1.3/0015

ALAPREN 20 TABLETS: 34/7.1.3/0016

Namibia : NS2

Reg. No.: ALAPREN 5 TABLETS: 04/7.1.3/1298

ALAPREN 10 TABLETS: 04/7.1.3/1299

ALAPREN 20 TABLETS: 04/7.1.3/1300

Botswana: S2

Reg. No.: ALAPREN 5 TABLETS: BOT0801166

ALAPREN 10 TABLETS: BOT0700982

ALAPREN 20 TABLETS: BOT0700983

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

27 September 2000

10. DATE OF REVISION OF THE TEXT

11 November 2022